Bassani

Bion Announces Voluntary Share Surrender

Retrieved on: 
Tuesday, April 2, 2024
Growth, Exercise, Livestock, Bassani, QB, OTC, Retirement, Bion, BNET, Security (finance)

If funding milestones are met, after the return of shares, Bion will have approximately 90M total shares (fully diluted).

Key Points: 
  • If funding milestones are met, after the return of shares, Bion will have approximately 90M total shares (fully diluted).
  • Details of the surrender, including which instruments will be returned and canceled, will be determined over the next several weeks.
  • Linda Bassani, Mr. Bassani’s widow, said, “Dom was committed to Bion and his vision of a sustainable livestock industry.
  • To build projects, Bion needs to bring on successor management, an operations team, and strategic partners.

Bion’s former CEO and Technology Co-inventor Passes

Retrieved on: 
Monday, November 13, 2023
Water quality, Strategic planning, Bion, Bassani, Atmosphere, R, QB, AND, OTC, Hospital, Livestock, BNET, Management

Mr. Bassani’s association with Bion began as a consultant in 2000, with a focus on strategic planning and special projects.

Key Points: 
  • Mr. Bassani’s association with Bion began as a consultant in 2000, with a focus on strategic planning and special projects.
  • In 2006, he assumed the role of CEO.
  • Mr. Bassani stepped down as Bion’s CEO in 2022, when Bion began the transition from R&D to commercialization of its technology.
  • To the Bassani family: you have our deepest condolences, and we look forward to completing his mission.”

PCCA Introduces Innovative New Compounding Base – SuspendIt® Anhydrous

Retrieved on: 
Wednesday, January 11, 2023
Viscosity, API, Development, PCCA, Bassani, Solubility, Water, Agitation, Growth, Patient, Patent, Bud, Pharmacy, Medicine, Operation, Taste, Quality control, Risk management, Research

“An anhydrous base offers many benefits to compounding pharmacies,” PCCA Chief Scientific Officer Gus Bassani said.

Key Points: 
  • “An anhydrous base offers many benefits to compounding pharmacies,” PCCA Chief Scientific Officer Gus Bassani said.
  • “We developed a unique anhydrous base that, in addition to the self-emulsifying properties, has an improved viscosity, which reduces when shaken and thickens when standing.
  • The technology is so unique that we have a patent pending.”
    Developing the unique anhydrous base was a collaborative effort.
  • Additionally, PCCA has created formulas for the most commonly prescribed APIs and plans to continue formula development and API testing.